Liminatus Pharma Inc. (NASDAQ:LIMN - Get Free Report) dropped 7.1% during mid-day trading on Wednesday . The company traded as low as $2.99 and last traded at $3.02. Approximately 645,888 shares changed hands during trading, a decline of 72% from the average daily volume of 2,273,840 shares. The stock had previously closed at $3.25.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen raised shares of Liminatus Pharma from a "sell" rating to a "hold" rating in a report on Saturday.
View Our Latest Report on LIMN
Liminatus Pharma Stock Performance
The firm's 50-day moving average is $6.22.
About Liminatus Pharma
(
Get Free Report)
Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.
See Also
Before you consider Liminatus Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liminatus Pharma wasn't on the list.
While Liminatus Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
